Physician profile
Danielle Leclair
NPI 1225121098
$2,642.43
in general payments reported to CMS, 2019-2025
16 companies · $993 in 2025
The $993 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $334 · 2023: $513 · 2024: $802 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.21 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $332.89 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $245.49 | 2022-2025 | |
| Lilly USA, LLC | $213.53 | 2023-2024 | Olumiant, Taltz |
| Journey Medical Corporation | $120.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $120.00 | 2025 | |
| Alkermes, INC. | $120.00 | 2025 | Lybalvi |
| Genzyme Corporation | $119.36 | 2025 | |
| Axsome Therapeutics, INC. | $104.58 | 2025 | Auvelity |
| Incyte Corporation | $96.61 | 2024 | Opzelura |
| Insmed, INC. | $93.46 | 2025 | Arikayce |
| Ucb, INC. | $81.83 | 2024 | Bimzelx |
| Sage Therapeutics, LLC | $76.80 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2023-2024 | Spevigo |
| Janssen Biotech, INC. | $20.97 | 2024 | Tremfya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Leclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.